Santen and twoXAR Announce Strategic Research Collaboration to Discover New Glaucoma Treatments
Santen and twoXAR, an artificial intelligence-driven biopharmaceutical company, announced that the two companies have entered into a strategic research collaboration focused on the identification of new drug candidates for glaucoma.
Under the agreement, twoXAR will use its proprietary computational drug discovery platform to discover, screen, and prioritize novel drug candidates with potential application in ocular indications, with a specific focus on glaucoma. Santen will have the exclusive right to develop and commercialize drug candidates arising from the collaboration. Further details of the agreement were not disclosed.
“We are pleased to have established this strategic collaboration with twoXAR which aims to deliver new treatment options for the millions of people living with glaucoma globally,” Naveed Shams, MD, PhD, Senior Corporate Officer, Chief Scientific Officer and Head of Global Research and Development at Santen, said in a company news release. “By leveraging twoXAR’s proprietary computational discovery platform to identify novel targets in areas of glaucoma, Santen further strengthens our R&D capabilities while expanding our pipeline of innovative therapeutic opportunities that help fulfill the unmet medical needs in ophthalmology.”
“This collaboration is an exciting example that demonstrates how software-driven approaches can lead the discovery of new drugs rather than simply supporting existing hypotheses,” Andrew A. Radin, cofounder and Chief Executive Officer of twoXAR, said in the news release. “The combination of twoXAR’s unique capabilities in artificial intelligence-driven drug discovery with Santen’s experience in ophthalmic product development and commercialization provides a foundation upon which we can rapidly discover and develop new therapeutic candidates to treat glaucoma and bring better treatment options to the millions of people living with this disease.”
You must be logged in to leave a comment.